Comparative immunogenicity of recombinant adenovirus-vectored vaccines expressing different forms of hemagglutinin (HA) proteins from the H5 serotype of influenza A viruses in mice

Virus Research

Volumn 155, Issue 1, 2011, Pages 156-162

  Hu, Xiangjing ^a   Meng, Weixu ^a   Dong, Zhenyuan ^a   Pan, Weiqi ^a   Sun, Caijun ^a   Chen, Ling ^a,b  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

HPAI; Immunogenicity; Influenza vaccine; Recombinant adenovirus vector

Indexed keywords

ADENOVIRUS VECTOR; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CODON; CONTROLLED STUDY; CROSS REACTION; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HONG KONG INFLUENZA; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; VIRUS RECOMBINANT; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CODON; CROSS REACTIONS; DRUG CARRIERS; FEMALE; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; SEQUENCE DELETION;

ADENOVIRIDAE; ANTIDESMA PLATYPHYLLUM; AVES; INFLUENZA A VIRUS; MUS;

EID: 78650525720     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.09.014     Document Type: Article

References (43)

1. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., Hoschler K., Zambon M.C. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(9523):1657-1664.
2. Carnero E., Li W., Borderia A.V., Moltedo B., Moran T., Garcia-Sastre A. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J. Virol. 2009, 83(2):584-597.
3. Cinatl J., Michaelis M., Doerr H.W. The threat of avian influenza A (H5N1). Part IV: development of vaccines. Med. Microbiol. Immunol. 2007, 196(4):213-225.
4. de Jong J.C., Claas E.C., Osterhaus A.D., Webster R.G., Lim W.L. A pandemic warning?. Nature 1997, 389(6651):554.
5. Gambotto A., Barratt-Boyes S.M., de Jong M.D., Neumann G., Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008, 371(9622):1464-1475.
6. Gao W.T., Soloff A.C., Lu X.H., Montecalvo A., Nguyen D.C., Matsuoka Y., Robbins P.D., Swayne D.E., Donis R.O., Katz J.M., Barratt-Boyes S.M., Gambotto A. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 2006, 80(4):1959-1964.
7. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., Bright R.A., Katz J.M., Mittal S.K., Sambhara S. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367(9509):475-481.
8. Hoffmann E., Krauss S., Perez D., Webby R., Webster R.G. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002, 20(25-26):3165-3170.
9. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(36):12915-12920.
10. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U.S.A. 2000, 97(11):6108-6113.
11. Horimoto T., Takada A., Fujii K., Goto H., Hatta M., Watanabe S., Iwatsuki-Horimoto K., Ito M., Tagawa-Sakai Y., Yamada S., Ito H., Ito T., Imai M., Itamura S., Odagiri T., Tashiro M., Lim W., Guan Y., Peiris M., Kawaoka Y. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 2006, 24(17):3669-3676.
12. Kreijtz J.H., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., Kuiken T., Fouchier R.A., Lower J., Osterhaus A.D., Sutter G., Rimmelzwaan G.F. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 2007, 195(11):1598-1606.
13. Li K.S., Guan Y., Wang J., Smith G.J., Xu K.M., Duan L., Rahardjo A.P., Puthavathana P., Buranathai C., Nguyen T.D., Estoepangestie A.T., Chaisingh A., Auewarakul P., Long H.T., Hanh N.T., Webby R.J., Poon L.L., Chen H., Shortridge K.F., Yuen K.Y., Webster R.G., Peiris J.S. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004, 430(6996):209-213.
14. Li S., Liu C., Klimov A., Subbarao K., Perdue M.L., Mo D., Ji Y., Woods L., Hietala S., Bryant M. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J. Infect. Dis. 1999, 179(5):1132-1138.
15. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., Gao Q., Zhang Z., Liu Y., Wang Z., Yang M., Sun R., Li C., Lin S., Ji M., Wang X., Wood J., Feng Z., Wang Y., Yin W. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368(9540):991-997.
16. Lipatov A.S., Webby R.J., Govorkova E.A., Krauss S., Webster R.G. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J. Infect. Dis. 2005, 191(8):1216-1220.
17. Liu M., Wood J.M., Ellis T., Krauss S., Seiler P., Johnson C., Hoffmann E., Humberd J., Hulse D., Zhang Y., Webster R.G., Perez D.R. Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics. Virology 2003, 314(2):580-590.
18. Neumann G., Fujii K., Kino Y., Kawaoka Y. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(46):16825-16829.
19. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., Hughes M., Perez D.R., Donis R., Hoffmann E., Hobom G., Kawaoka Y. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(16):9345-9350.
20. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., Zambon M.C. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357(9272):1937-1943.
21. Nicolson C., Major D., Wood J.M., Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005, 23(22):2943-2952.
22. Palmer D., Dowdle W., Coleman M., Schild G. Advanced Laboratory Techniques for Influenza Diagnosis: Procedural Guide 1975, US Department of Health, Education, and Welfare, Atlanta, pp. 25-62.
23. Peiris J.S., Yu W.C., Leung C.W., Cheung C.Y., Ng W.F., Nicholls J.M., Ng T.K., Chan K.H., Lai S.T., Lim W.L., Yuen K.Y., Guan Y. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004, 363(9409):617-619.
24. Qiu J.T., Liu B.D., Tian C.J., Pavlakis G.N., Yu X.F. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 Gag by using DNA expression vectors that target Gag antigen to the secretory pathway. J. Virol. 2000, 74(13):5997-6005.
25. Robinson H.L., Boyle C.A., Feltquate D.M., Morin M.J., Santoro J.C., Webster R.G. DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J. Infect. Dis. 1997, 176 (Suppl.):S50-S55.
26. Scheerlinck J.Y. Genetic adjuvants for DNA vaccines. Vaccine 2001, 19(17-19):2647-2656.
27. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415(6869):331-335.
28. Singh I., Doms R.W., Wagner K.R., Helenius A. Intracellular transport of soluble and membrane-bound glycoproteins: folding, assembly and secretion of anchor-free influenza hemagglutinin. EMBO J. 1990, 9(3):631-639.
29. Stevens J., Blixt O., Tumpey T.M., Taubenberger J.K., Paulson J.C., Wilson I.A. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006, 312(5772):404-410.
30. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., Xu X., Lu X., Katz J., Cox N., Matsuoka Y. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003, 305(1):192-200.
31. Subbarao K., Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol. 2007, 7(4):267-278.
32. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., Hemphill M., Rowe T., Shaw M., Xu X., Fukuda K., Cox N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279(5349):393-396.
33. Takada A., Kuboki N., Okazaki K., Ninomiya A., Tanaka H., Ozaki H., Itamura S., Nishimura H., Enami M., Tashiro M., Shortridge K.F., Kida H. Avirulent avian influenza virus as a vaccine strain against a potential human pandemic. J. Virol. 1999, 73(10):8303-8307.
34. Tian G., Zhang S., Li Y., Bu Z., Liu P., Zhou J., Li C., Shi J., Yu K., Chen H. Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics. Virology 2005, 341(1):153-162.
35. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., Wolff M., Rabinovich G., Blackwelder W., Katz J.M. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19(13-14):1732-1737.
36. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., Uiprasertkul M., Boonnak K., Pittayawonganon C.S. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 2005, 352(4):333-340.
37. Van Kampen K.R., Shi Z., Gao P., Zhang J., Foster K.W., Chen D.T., Marks D., Elmets C.A., Tang D.C. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005, 23(8):1029-1036.
38. Wang S., Farfan-Arribas D.J., Shen S., Chou T.H., Hirsch A., He F., Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006, 24(21):4531-4540.
39. Wang S., Heilman D., Liu F., Giehl T., Joshi S., Huang X., Chou T.H., Goguen J., Lu S. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 2004, 22(25-26):3348-3357.
40. Wang S.X., Taaffe J., Parker C., Solorzano A., Cao H., Garcia-Sastre A., Lu S. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J. Virol. 2006, 80(23):11628-11637.
41. Webby R.J., Perez D.R., Coleman J.S., Guan Y., Knight J.H., Govorkova E.A., McClain-Moss L.R., Peiris J.S., Rehg J.E., Tuomanen E.I., Webster R.G. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004, 363(9415):1099-1103.
42. Wood J.M., Robertson J.S. From lethal virus to life-saving vaccine: the development of inactivated influenza vaccines for pandemic influenza. Nat. Rev. Microbiol. 2004, 2(10):842-847.
43. World Health Organization Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO 2010, Available at:. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_05_06/en/index.h%20ml.